Toppublicaties

Prostaatcarcinoom

Geselecteerd door: Prostaatcarcinoom
  • juli 2023

Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial

  • Sweeney CJ, Martin AJ, Stockler MR, et al.
  • juni 2023

Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial

  • Fizazi K, Herrmann K, Krause BJ, et al.
  • juni 2023

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

  • Sweeney CJ, Martin AJ, Stockler MR, et al.
Duiding door Dr. André Bergman

Rucaparib verbetert progressieve overleving gemetastaseerde prostaatkanker
  • februari 2023

Rucaparib or Physician's Choice in Metastatic Prostate Cancer

  • Fizazi K, Piulats JM, Reaume MN, et al.
  • december 2022

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up

  • Balar AV, Castellano DE, Grivas P, et al.
  • november 2022

Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial

  • Tran PT, Lowe K, Tsai HL, et al.
Duiding door dr. André Bergman

Combinatie enzalutamide en docetaxel vertraagt progressie prostaatcarcinoom
  • oktober 2022

Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study

  • Prof Axel S Merseburger, Gerhardt Attard, Lennart Åström, et al.
  • oktober 2022

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

  • James P Buteau, Andrew J Martin, PhD Prof Louise Emmett, et al.
  • augustus 2022

Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST)

  • Johnathan K. Joffe, Fay H. Cafferty , Laura Murphy, et al.
  • mei 2022

The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.

  • Pollack A, Karrison TG, Balogh AG, et al.
  • mei 2022

Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial.

  • Hussain SA, Lester JF, Jackson R, et al.
Duiding door dr. André Bergman

Androgeendeprivatie, docetaxel en abirateron effectief tegen prostaatkanker
  • april 2022

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.

  • Fizazi K, Foulon S, Carles J, et al.
Gedownload van https://medischeoncologie.nl/ op 22-09-2023 om 05:55. Copyright (C) 2023 BPM Medica.

Deel deze pagina